Trial Profile

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veverimer (Primary)
Indications Metabolic acidosis; Renal failure
Focus Registrational; Therapeutic Use
Acronyms VALOR-CKD
Sponsors Tricida

Most Recent Events

01 Mar 2024 Results Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis, published in the Journal of the American Society of Nephrology
08 Feb 2024 This trial has been completed in Portugal (Date of the global end of the trial : 27-Sep-2022),
12 Jan 2023 This trial has been completed in Poland (Date of the global end of the trial : 27-Sep-2022), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com